Skip to main content

Table 2 Quality assessment for included trials

From: Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials

Trial

Sequence generation

Allocation concealment

Blinding

Incomplete outcome data

Selective outcome reporting

Other source of bias

participants

personnel

outcome assessors

FOSIDIAL 2006 [9]

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

SAFIR 2014 [11]

LOW

UNCLEAR

LOW

LOW

UNCLEAR

LOW

LOW

LOW

Yilmaz 2010 [18]

UNCLEAR

UNCLEAR

HIGH

HIGH

HIGH

LOW

LOW

LOW

Philip 2003 [14]

LOW

LOW

HIGH

HIGH

HIGH

LOW

LOW

LOW

HDPAL 2014 [20]

LOW

LOW

HIGH

HIGH

HIGH

LOW

LOW

LOW

Suzuki 2008 [10]

LOW

LOW

HIGH

HIGH

HIGH

LOW

LOW

LOW

Takahashi 2006 [8]

LOW

LOW

HIGH

HIGH

LOW

LOW

UNCLEAR

UNCLEAR

OCTOPUS 2013 [19]

UNCLEAR

UNCLEAR

HIGH

HIGH

LOW

LOW

LOW

LOW

Suzuki 2004 [15]

LOW

LOW

HIGH

HIGH

HIGH

LOW

LOW

LOW

Wang J [16]

UNCLEAR

UNCLEAR

UNCLEAR

UNCLEAR

UNCLEAR

LOW

LOW

UNCLEAR

Zhong H [17]

UNCLEAR

UNCLEAR

UNCLEAR

UNCLEAR

UNCLEAR

LOW

LOW

UNCLEAR

  1. Assessment of risk bias according to the Cochrane Collaboration’s tool, low risk of bias was represented as “LOW” and high risk of bias was “HIGH”